The title of “startup advisor” is one of the most loosely applied labels in the healthcare innovation space. It covers everything from a founder’s college roommate who offered to make a few introductions to a former hospital CMO who is actively shaping a company’s clinical strategy, regulatory approach, and commercial positioning every month.
That range matters, because the expectations attached to the title vary just as widely. Clinicians who enter advisory relationships without a clear picture of what advisors actually do, what the role genuinely requires, and what a functioning advisory engagement looks like, often end up in one of two situations: they contribute far more than the structure compensates or acknowledges, or they contribute far less than the company needed and the relationship quietly fades.
This article is a precise look at what startup advisors actually do in practice, how healthcare advisory roles differ from those in other sectors, what a well-functioning engagement looks like from both sides, and what you should expect before committing your time and reputation to any specific relationship.
The Gap Between What Advisors Are Asked to Do and What They Actually Provide
Most advisory relationships in the startup world begin with a founder asking for something specific: an introduction to a health system, feedback on a clinical trial design, help thinking through a regulatory pathway, a second opinion on a go-to-market strategy. That initial ask is usually genuine and usually useful.
The gap emerges in the months that follow. The initial ask gets answered. The founder moves on to the next problem. The advisor attends a quarterly meeting, reviews a slide deck, offers a few observations, and the relationship gradually becomes more nominal than functional.
This pattern is not a failure of intention on either side. It is a structural failure of how most advisory relationships are set up. When the scope of the engagement is not clearly defined from the beginning, when there is no documented expectation of what the advisor is accountable for and what the company is accountable for in return, and when compensation is not tied to specific contributions, the relationship defaults to the lowest-friction version of itself.
According to research on advisory board effectiveness published by MIT Sloan Management Review, the advisory relationships that produce the most value for both founders and advisors are consistently the ones with explicit scope, defined time commitment, and compensation structures tied to specific contributions rather than general availability. Vague relationships produce vague outcomes, and the advisor’s reputation is part of what gets vaguely associated with those outcomes.
Understanding what startup advisors actually do in high-functioning relationships is the foundation for entering any advisory engagement with the right expectations and the right structure.
The Formal Definition and Why It Misses the Point
The standard definition of a startup advisor is something like: an experienced external professional who provides guidance, expertise, and connections to a company in exchange for equity, cash, or both, without the legal obligations of a board director or the employment obligations of an executive.
That definition is accurate as far as it goes. It explains what advisors are not: they are not employees, they are not fiduciaries, they are not day-to-day operators. What it does not explain is what high-value advisors actually do in practice, which looks considerably more specific and more demanding than “provides guidance.”
The formal definition also obscures an important distinction between advisory relationships that are primarily about credibility transfer and those that are primarily about expertise deployment. A company that adds a well-known physician to its advisory board because the name on their website helps with investor conversations is using that advisor’s reputation, not their expertise. A company that brings in a clinical operator to stress-test its workflow adoption assumptions and reshape its regulatory strategy is using their expertise. Both are technically “advisory relationships.” They produce entirely different outcomes, and they deserve entirely different compensation structures.
When clinicians who are ready to contribute genuine expertise enter advisory relationships structured around credibility transfer, the mismatch surfaces quickly. Your input is received politely and not acted on. The questions you are asked are designed to confirm existing decisions rather than challenge them. Your reputation is on the slide deck but your judgment is not in the room where decisions are made.
Knowing the difference before you commit is considerably more valuable than discovering it six months in.
What Startup Advisors Do in Practice
In a well-structured advisory relationship, the work of a startup advisor falls into five categories that happen in different proportions depending on the stage of the company and the domain of the advisor.
Domain translation. The single most consistent contribution high-value advisors make is translating complex domain knowledge into decisions the founding team can act on. In healthcare, this almost always means taking clinical, regulatory, or operational complexity and converting it into a form that informs product decisions, commercial strategy, or investment positioning. A regulatory advisor does not just explain what the FDA requires. They help the team understand which pathway is realistic for their specific product at their specific stage of validation, and what the filing timeline means for their capital needs.
Network activation. Effective advisors make specific introductions that would otherwise take the founding team months or years to develop independently. This is not casual networking. It is targeted connection-making: facilitating a pilot conversation with a health system contact, introducing the CEO to a payer relationship, or connecting the clinical team with a principal investigator who can run a validation study. According to Harvard Business Review research on high-performing professional networks, the most valuable professional introductions are those that bridge domains and carry contextual endorsement. When a respected clinician makes a warm introduction for a portfolio company, that introduction carries the weight of the advisor’s credibility, not just their contact list.
Assumption stress-testing. Healthcare startups make clinical, regulatory, and commercial assumptions that often go unchallenged because no one on the founding team has operated inside the systems those assumptions depend on. An experienced clinical advisor who has worked in the hospital environment a company is trying to sell into, or who has navigated the regulatory pathway a company is planning to follow, can identify which assumptions are fragile before they become expensive corrections. This is one of the highest-leverage contributions an advisor makes and one of the hardest to quantify, because what it prevents never shows up in the results.
Credibility transfer in external conversations. There are specific situations where an advisor’s direct participation in a conversation changes the nature of that conversation: a health system meeting where the clinical advisor’s institutional affiliation opens the door, an investor pitch where the advisory board composition signals clinical seriousness, a regulatory pre-submission meeting where an advisor with relevant FDA experience provides the kind of informed perspective that shapes how the agency engages. This function is legitimate and valuable, but it should be clearly understood as one component of an advisory contribution, not the primary one.
Ongoing strategic counsel. At the board advisory level, experienced advisors engage with company direction questions: market positioning, partnership strategy, capital allocation, organizational structure, and talent decisions. This type of contribution requires systems-level judgment that comes from having operated at the executive level in healthcare organizations, and it is the function most often associated with formal advisory board roles at growth-stage companies.
Advisory Board vs Board of Directors: The Distinction That Matters
One of the most common sources of confusion for clinicians entering advisory work is the difference between serving on an advisory board and serving on a formal board of directors. These are not variations of the same role. They are structurally different engagements with different legal obligations, different authority, and different accountability.
A board of directors has legal authority over the company. Directors have fiduciary duties to shareholders, vote on major company decisions including executive appointments, capital raises, and strategic direction, and carry legal liability for the governance of the company. Joining a board of directors is a serious legal commitment that requires a thorough understanding of the company’s financial position, governance structure, and legal exposure.
An advisory board has no legal authority. Advisory board members do not vote on company decisions, do not carry fiduciary duties, and do not bear legal liability for company outcomes. They provide expertise, introductions, and strategic perspective, and they are compensated through equity or cash for that contribution. The engagement is informal relative to a board directorship, which is exactly why it is the appropriate starting structure for most clinicians who are entering startup engagement for the first time.
According to Investopedia’s analysis of startup governance structures, advisory boards are particularly valuable for early-stage companies that need external expertise and credibility but are not yet at the stage where formal board governance adds more value than flexibility. Healthcare startups frequently establish advisory boards well before they establish formal boards of directors, precisely because clinical and regulatory expertise is needed long before the company has the investor backing that typically drives formal board composition.
The practical implication for clinicians is this: if you are being asked to join a company’s formal board of directors rather than its advisory board, the due diligence required before accepting is considerably more intensive. You should understand the company’s cap table, its existing board composition, its legal and financial obligations, and the specific governance responsibilities you would be assuming. Most first advisory engagements for clinicians are advisory board roles, not formal director positions, and that is an appropriate starting point.
What a Healthcare Startup Specifically Needs From an Advisor
The demand for clinical advisors in healthcare startups is real and growing. The global healthcare IT market is projected to reach $974 billion by 2027, driven substantially by digital health, AI-enabled clinical tools, and value-based care infrastructure, all of which require embedded clinical expertise to navigate successfully.
What makes healthcare different from other startup sectors is the consequence of getting the clinical, regulatory, and workflow assumptions wrong. A consumer technology company that misreads its market can pivot relatively quickly. A healthcare startup that builds its entire clinical validation strategy around the wrong FDA pathway, or that designs a workflow integration based on how clinicians ought to behave rather than how they actually behave under real conditions, faces corrections that are measured in years and millions of dollars.
The specific things healthcare startups most consistently need from clinical advisors, based on where they most consistently fail without that input:
Honest clinical workflow assessment. Does the product fit into how care actually gets delivered, or into how a non-clinical team imagines care gets delivered? The gap between those two is where most digital health adoption failures originate.
Regulatory pathway clarity. Which FDA classification applies, what the pre-submission process looks like, whether the clinical evidence standard the company is aiming for is appropriate for the pathway they are pursuing, and what the realistic timeline looks like given the company’s current stage of validation. This is specialized knowledge that most founding teams do not have and cannot develop quickly enough to avoid costly mistakes.
Payer and reimbursement strategy. Whether the product fits an existing CPT code or requires a new reimbursement pathway, what the evidence standard a payer will require looks like, and how long the reimbursement approval process typically takes in the specific clinical category the company is operating in.
Institutional relationship access. Health systems, large physician groups, academic medical centers, and payer organizations move through structured procurement processes that are resistant to cold outreach. A clinical advisor with existing relationships inside those organizations can compress timelines that would otherwise take years.
What You Should Expect From the Engagement on Your Side
A well-structured advisory role makes specific demands on your time and your professional judgment. Being clear about what those demands are before entering any advisory relationship prevents the most common form of advisory frustration, which is discovering that the actual engagement looks nothing like what you expected when you agreed to it.
Time commitment. A meaningful advisory engagement typically requires two to eight hours per month depending on the intensity of the relationship and the stage of the company. Two hours covers a monthly call and asynchronous review of materials. Eight hours includes active involvement in specific strategic or commercial workstreams. Anything consistently above eight hours per month without corresponding adjustment to the compensation structure is a signal that the scope has drifted beyond what the original agreement contemplated.
Availability and responsiveness. Founders engage advisors because they need access to expertise at specific moments, often when a decision is time-sensitive. An advisor who is difficult to reach, slow to respond, or consistently unavailable during critical periods provides less value than one who maintains reliable access even within a bounded time commitment. Defining your availability upfront, including preferred communication channels and response time expectations, prevents misalignment that creates frustration on both sides.
Honest input, including input the founder may not want to hear. The most valuable thing an advisor does is provide the kind of direct assessment that an employee cannot provide because of their position and that a co-founder cannot provide because of their proximity. Advisors who soften clinical assessments to avoid awkward conversations with founders are not functioning as advisors. They are functioning as cheerleaders, and they are providing considerably less value than the equity they hold suggests.
Professional discretion. Advisory roles expose you to proprietary information: clinical strategies, regulatory planning, financial structures, and business development conversations. The confidentiality obligations in your advisory agreement are not formalities. They reflect the genuine sensitivity of what you are accessing, and honoring them is part of what makes you a trustworthy advisor whose involvement means something to future companies that consider you.
The Signs That an Advisory Relationship Is Working
Because advisory relationships are loosely structured relative to employment, it can be genuinely difficult to know whether the engagement is functioning well or gradually drifting toward irrelevance. There are a small number of indicators that distinguish advisory relationships that are producing value from those that are not.
The founder reaches out between scheduled meetings when they encounter a problem in your domain. This is the clearest signal that your input is being actively used rather than passively received. If the only time you hear from the company is when a scheduled meeting is on the calendar, the relationship has probably become more nominal than functional.
Your recommendations lead to visible changes in company decisions. You can trace a regulatory strategy adjustment, a clinical validation design decision, or a commercial targeting choice back to a conversation you had with the founding team. That traceability is the evidence that your judgment is being deployed, not just collected.
The company makes introductions on your behalf in return. The best advisory relationships are genuinely reciprocal. Founders who value an advisor’s contribution look for ways to return that contribution through introductions to other founders, investors, or opportunities. If the relationship is entirely one-directional over an extended period, it is worth having a direct conversation about whether the structure is working for both parties.
How HBA Structures Advisory Roles So They Produce Outcomes
Health Board Advisors was built around a specific diagnosis: advisory relationships in healthcare fail most often not because advisors lack expertise but because the matching process that produces the introduction does not evaluate whether the company is ready to deploy that expertise before the introduction is made.
The Advisor Fellowship creates a structured matching pathway that addresses that problem directly. The Leadership Maximizer program maps each fellow’s domain, leadership profile, execution orientation, and stage fit through a 5-dimensional assessment. Every venture in the ecosystem has passed through the Pathfinder program, which evaluates founder execution readiness, clinical validity, regulatory positioning, and commercial infrastructure using the Founder Execution Risk Filter before any advisory match is made.
The result is that when a Core or Circle Fellow is introduced to an advisory opportunity through HBA, both parties enter the conversation with shared context: the advisor knows the company has been assessed for execution readiness, and the company knows the advisor has been evaluated for the specific type of contribution they provide. The preliminary work of establishing that mutual fit has already been completed.
The expert directory gives fellows visibility across the ecosystem, tagged by specific domain across clinical validation, FDA approval, AI governance, revenue cycle management, go-to-market strategy, board governance, and more. Founders searching for a matched clinical advisor find the right person directly rather than through generic outreach.
For fellows who want to engage with vetted ventures before formal advisory commitments, the monthly Venture Vitality Roundtable and Hot or Not startup pitch sessions at healthboardadvisors.com/events provide direct exposure to companies inside the ecosystem in a structured, low-commitment format.
Connect with HBA
Health Board Advisors connects vetted clinicians, operators, and healthcare executives with startup advisory opportunities where the matching has been done before the introduction is made.
If you are a practicing clinician who wants advisory roles that deploy your judgment rather than display your credentials, the fellowship is where that work begins.
Or explore the Advisor Fellowship to understand how Core and Circle Fellow matching works before you apply.
About the Author
Val Alexandre Torres, MD, MBA
Val Alexandre Torres is Co-Founder and Chief Operating Officer of Health Board Advisors. A healthcare innovation strategist, physician leader, and ecosystem builder, he specializes in connecting clinicians, operators, investors, and founders to accelerate healthcare innovation and adoption.
Through HBA’s Triple Match framework, Val helps align clinical expertise, operational execution, and strategic capital to support healthcare ventures seeking scalable impact. He is recognized for building multidisciplinary collaborations that bridge healthcare, technology, investment, and leadership development.
Related Articles
How to Become a Startup Advisor in Healthcare
The practical guide to transitioning from practicing clinician to startup advisor: how to define your advisory domain, build the profile that gets you matched to the right ventures, and evaluate compensation structures that reflect your contribution.
Advisory Shares vs Equity: What Healthcare Advisors Should Negotiate
A precise look at how advisory compensation works in healthcare startups, what benchmarks apply at each stage, and how to structure agreements that protect your time and your reputation.
How to Land a Board Seat as a Practicing Clinician
For clinicians who are ready to move beyond advisory roles into formal board positions, this article covers the positioning, matching, and evaluation work that produces board seats that actually deploy your clinical judgment.
Want to understand how HBA evaluates the ventures you would be advising before any introduction is made? Read about the Pathfinder program and the Founder Execution Risk Filter to see how execution readiness is assessed before any advisory matching occurs.
Related Posts :
